Checkmate Pharmaceuticals Overview

  • Founded
  • 2015

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 31

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $210M

Checkmate Pharmaceuticals General Information

Description

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 245 Main Street
  • 2nd Floor
  • Cambridge, MA 02142
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Checkmate Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 31-May-2022 $210M 00000 00000 Completed Generating Revenue
6. IPO 07-Aug-2020 0000 00000 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 09-Jun-2020 000.00 00000 00000 Completed Generating Revenue
4. Early Stage VC (Series B) 27-Jan-2020 0000 0000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Dec-2018 0000 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 02-Jun-2017 $27M $52M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 16-Feb-2017 $25M $25M 0000 Completed Generating Revenue
To view Checkmate Pharmaceuticals’s complete valuation and funding history, request access »

Checkmate Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 25,000,000 $0.000100 $0.08 $1 $1 1x $1 19.06%
To view Checkmate Pharmaceuticals’s complete cap table history, request access »

Checkmate Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its pr
Biotechnology
Cambridge, MA
31 As of 2022
00000
0000 0000-00-00
000000&0 00000

000000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mol
0000 000000000
San Carlos, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Checkmate Pharmaceuticals Competitors (53)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Jounce Therapeutics Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000000 Formerly VC-backed San Carlos, CA 00 00000 000000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000000 Venture Capital-Backed Seattle, WA 00 00000 000000000 00000
You’re viewing 5 of 53 competitors. Get the full list »

Checkmate Pharmaceuticals Patents

Checkmate Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020372478-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 0000000000
EP-4048795-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 0000000000
CA-3155202-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 0000000000
AU-2019255370-A1 Synthetic rig-i-like receptor agonists Pending 19-Apr-2018 0000000000
CA-3093715-A1 Synthetic rig-i-like receptor agonists Pending 19-Apr-2018 C12N15/117
To view Checkmate Pharmaceuticals’s complete patent history, request access »

Checkmate Pharmaceuticals Board Members (12)

Name Representing Role Since
Nilesh Kumar Ph.D Self Board Member 000 0000
You’re viewing 1 of 12 board members. Get the full list »

Checkmate Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Checkmate Pharmaceuticals Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BrightEdge (Georgia) Impact Investing Minority 000 0000 000000 0
Clough Capital Partners Hedge Fund Minority 000 0000 000000 0
Decheng Capital Venture Capital Minority 000 0000 000000 0
Eight Roads Corporate Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »